11 min listen
ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
11 minutes
Released:
Nov 8, 2022
Format:
Podcast episode
Description
Thiazides are recommended first line agents for the treatment of hypertension. They have been demonstrated to lower cardiovascular disease. Which thiazide to choose has been a long-standing issue. In this interview, Areef Ishani MD, MS and W. Douglas Weaver MD, MACC discuss AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Released:
Nov 8, 2022
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: Universal Definition of HF Syndrome: Evolving Strategies: The new universal heart failure (HF) definition will be easier for patients and clinicians to understand and will provide standardization across different societies. In this interview, Allen Taylor, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research